Abstract
The enzyme indoleamine 2,3-dioxygenase (IDO, EC 1.13.11.42) belongs to the family of heme-containing oxidoreductases and catalyzes the first and rate-limiting step in the kynurenine pathway, the major pathway of tryptophan metabolism. IDO is folded into one large and one small distinct α-helical domains, with the heme prosthetic ring positioned between them. The enzyme, through the oxidative properties of the Fe3+ atom present at the centre of the heme ring, catalyses the oxidative cleavage of the pyrrole ring of L-Trp to generate N-formyl-kynurenine. The active IDO conformer exists only in the presence of reducing cofactors (such as cytochrome b5), requiring the single electron reduction of ferric-to-ferrous iron (Fe3+ Fe2+), which facilitates binding of L-Trp and O2 to the enzyme active site. IDO, through production of kynurenine and other downstream metabolites, can regulate immune responses, suppressing effector T-cell function and favouring the differentiation of regulatory T cells. Local expression of the enzyme during inflammation is another self-protection mechanism, which limits antigen-specific immune responses, especially in some organs, as the central nervous system. The detailed knowledge of the structural and functional properties of IDO, was a fundamental step to design and develop new molecules for the pharmacological inhibition of IDO activity in several clinical settings.
Keywords: Indoleamine 2,3-dioxygenase, Immune tolerance, X-ray structure of oxygenases, enzyme, heme-containing oxidoreductases, kynurenine, tryptophan metabolism, helical domains, N-formyl-kynurenine, IDO
Current Medicinal Chemistry
Title: Biochemical Properties of Indoleamine 2,3-dioxygenase: From Structure to Optimized Design of Inhibitors
Volume: 18 Issue: 15
Author(s): S. Lancellotti, L. Novarese and R. De Cristofaro
Affiliation:
Keywords: Indoleamine 2,3-dioxygenase, Immune tolerance, X-ray structure of oxygenases, enzyme, heme-containing oxidoreductases, kynurenine, tryptophan metabolism, helical domains, N-formyl-kynurenine, IDO
Abstract: The enzyme indoleamine 2,3-dioxygenase (IDO, EC 1.13.11.42) belongs to the family of heme-containing oxidoreductases and catalyzes the first and rate-limiting step in the kynurenine pathway, the major pathway of tryptophan metabolism. IDO is folded into one large and one small distinct α-helical domains, with the heme prosthetic ring positioned between them. The enzyme, through the oxidative properties of the Fe3+ atom present at the centre of the heme ring, catalyses the oxidative cleavage of the pyrrole ring of L-Trp to generate N-formyl-kynurenine. The active IDO conformer exists only in the presence of reducing cofactors (such as cytochrome b5), requiring the single electron reduction of ferric-to-ferrous iron (Fe3+ Fe2+), which facilitates binding of L-Trp and O2 to the enzyme active site. IDO, through production of kynurenine and other downstream metabolites, can regulate immune responses, suppressing effector T-cell function and favouring the differentiation of regulatory T cells. Local expression of the enzyme during inflammation is another self-protection mechanism, which limits antigen-specific immune responses, especially in some organs, as the central nervous system. The detailed knowledge of the structural and functional properties of IDO, was a fundamental step to design and develop new molecules for the pharmacological inhibition of IDO activity in several clinical settings.
Export Options
About this article
Cite this article as:
Lancellotti S., Novarese L. and De Cristofaro R., Biochemical Properties of Indoleamine 2,3-dioxygenase: From Structure to Optimized Design of Inhibitors, Current Medicinal Chemistry 2011; 18 (15) . https://dx.doi.org/10.2174/092986711795656108
DOI https://dx.doi.org/10.2174/092986711795656108 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Taurine, Bone Growth and Bone Development
Current Nutrition & Food Science Altered Prolylcarboxypeptidase Expression and Function in Response to Different Risk Factors of Diabetes
Cardiovascular & Hematological Agents in Medicinal Chemistry Patent Selections:
Recent Patents on Cardiovascular Drug Discovery Pharmacological Treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults
Current Psychiatry Reviews Functions of S100 Proteins
Current Molecular Medicine Novel Agents Targeting Nitric Oxide
Current Vascular Pharmacology The Use of Exercise Echocardiography in the Evaluation of Mitral Regurgitation
Current Cardiology Reviews Peroxisome Proliferator Activated Receptor α Ligands as Anticancer Drugs Targeting Mitochondrial Metabolism
Current Pharmaceutical Biotechnology An Insight of Novel Pharmacological Therapies in Hypertrophic Cardiomyopathy
Medicinal Chemistry Development of Inhibitors of the Aspartyl Protease Renin for the Treatment of Hypertension
Current Protein & Peptide Science Targets for Anti-T. cruzi Drugs in the Post-Genomic Era
Current Enzyme Inhibition Myocardial Infarction with Non Obstructive Coronary Atherosclerosis: A Case Report
New Emirates Medical Journal New Therapeutic Aspects of Inflammatory Cardiomyopathy
Current Pharmaceutical Design Proteomics to Identify Novel Biomarkers and Therapeutic Targets in Cardiovascular Disease
Letters in Drug Design & Discovery Withdrawal Notice: COVID-19: Outbreak to Global
Anti-Infective Agents Valve in Valve Trans-Catheter Aortic Valve Replacement Followed by LVAD Deactivation in the Setting of Recovered Systolic Function
Current Cardiology Reviews High-Density Lipoprotein: Key Molecule in Cholesterol Efflux and the Prevention of Atherosclerosis
Current Pharmaceutical Design Cardiac Mitochondrial Alterations Observed in Hyperglycaemic Rats - What Can We Learn From Cell Biology?
Current Diabetes Reviews Effect of a New Class of Compounds of the Group of Substituted 5R1, 6H2-1,3,4-thiadiazine-2-amines on the Inflammatory and Cytokine Response in Experimental Myocardial Infarction
Current Vascular Pharmacology Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors
Current Cancer Drug Targets